Breast Cancer

P2, N=60, Recruiting, University of Texas Southwestern Medical Center | Trial primary completion date: Apr 2026 --> Apr 2027

P1/2, N=1132, Recruiting, Hoffmann-La Roche | N=792 --> 1132

P1, N=60, Recruiting, Immunomic Therapeutics, Inc.

P2, N=43, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

To our knowledge, this is the first comprehensive MR study linking sex hormone-related factors (E2, EST, BCAR3) to increased oral cavity cancer risk. Further validation is needed to explore prevention and treatment implications.

In a multivariate regression analysis the cumulative dose of anthracycline (OR = 1.01, 95% CI: 1.00-1.01, p = 0.002) and LVEF at baseline (OR = 0.83, 95% CI: 0.70-0.99, p = 0.0344) were independent predictors of a cardiotoxic effect. Trastuzumab-related cardiotoxicity resulting in early treatment discontinuation negatively influences DFS, but does not seem to influence OS.

HER2-low status was associated with worse OS in breast cancer patients with certain negative prognostic factors compared with HER2-zero status. Additionally, HER2-low1+ and HER2-low2+/ISH(-) subgroups predominantly exhibited HR+ status.

We developed and validated a well-calibrated nomogram for predicting DFS in patients with HR+/HER- breast cancer. This nomogram uniquely integrates MHR with clinicopathological factors to predict prognosis in HR+/HER2- breast cancer and can facilitate individualized therapeutic planning.

Antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) offer new and potent options for curing for curing hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-low advanced breast cancer; however, comparisons in terms of their relative effectiveness and safety concerns are lacking. Compared with other ADC drugs, T-DXd showed relatively better treatment characteristics, better PFS benefit, and relatively low incidence of serious AEs (SAEs). Combined with RCTs and real-world data, T-DXd has potential advantages in this population.

Utidelone plus capecitabine has brought therapeutic and survival benefits in the second-line treatment of patients with advanced breast cancer (ABC). Utidelone demonstrates favorable efficacy and safety in patients with refractory ABC, particularly in HR+/HER2- patients. The combination of utidelone with anti-angiogenic therapy shows promising intracranial anti-tumor activity and is expected to be a preferred option for ABC in subsequent lines of treatment.

Camptothecin, CDK9 and multiple ion-channel inhibitors displayed selective efficacy in high-risk samples &lsqb;half-maximal inhibitory concentration (IC50) shift P<0.01]. Our study provided the first CHRG-based prognostic model that simultaneously captures tumor-intrinsic aggressiveness and immune-evasive capacity in BC, offering quantitative biomarkers and actionable therapeutic targets for precision oncology.

CRNDE 84aa is highly expressed in breast cancer and functions as a tumor antigen that activates anti-tumor immunity. This study suggests that lncRNA-encoded peptides represent a viable source of tumor antigens for immunologically "cold" tumors such as breast cancer, highlighting their potential as novel targets for immunotherapy.